NUZ

Neurizon redeemed convertible notes at a 3.6% premium to face value and secured a 2-month share-sale standstill from Obsidian, demonstrating disciplined capital stewardship while maintaining funding through HEALEY ALS Phase 2/3 topline. The move is defensive and housekeeping-oriented, not a clinical or commercial trigger.

NIH-funded Expanded Access Program broadens NUZ-001 exposure to 200 ALS patients ineligible for trials, generating long-term safety and biomarker data alongside the Phase 2/3 program; funding covers all drug supply and regulatory costs, de-risking operational burden. Stock has rebounded +13% over 5d but remains -60% off 252d high, suggesting market has not yet fully priced the program's value as a de-risking and data-generation catalyst ahead of Phase 2/3 readout (late Q2 2027).

Neurizon has appointed an experienced pharma executive with proven licensing and commercialisation credentials ahead of NUZ-001 late-stage trial topline (late Q2 2027); the move indicators confidence in execution and preparation for post-trial value pathways. However, the announcement is a leadership reshuffle, not a clinical or financial catalyst, and carries material weight only if the market had doubted prior management capability.